Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease-Reference-Cited by-同舟云学术

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

Published:2010-05-06 Issue:18 Volume:362 Page:1663-1674
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Stone Gregg W.,Rizvi Ali,Newman William,Mastali Kourosh,Wang John C.,Caputo Ronald,Doostzadeh Julie,Cao Sherry,Simonton Charles A.,Sudhir Krishnankutty,Lansky Alexandra J.,Cutlip Donald E.,Kereiakes Dean J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910496

Cited by 770 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes with biodegradable versus durable polymer drug-eluting stents in patients with ST-elevation myocardial infarction;Cardiovascular Revascularization Medicine;2024-08

2. Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery;Journal of the American College of Cardiology;2024-08

3. Revolutionizing Cardiovascular Frontiers: A Dive Into Cutting-Edge Innovations in Coronary Stent Technology;Cardiology in Review;2024-05-06

4. Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction;Texas Heart Institute Journal;2024-05-01

5. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial;The Lancet;2024-05